RNAZ - Transcode Therapeutics, Inc.

9.6
0.270   2.813%

Share volume: 11,008
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$9.33
0.27
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 31%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.74%
1 Month
-10.45%
3 Months
14.97%
6 Months
-11.60%
1 Year
511.46%
2 Year
1,215.07%
Key data
Stock price
$9.60
P/E Ratio 
0.00
DAY RANGE
$9.11 - $10.03
EPS 
-$42.93
52 WEEK RANGE
$0.22 - $20.99
52 WEEK CHANGE
$600.73
MARKET CAP 
8.962 M
YIELD 
N/A
SHARES OUTSTANDING 
916.968 K
DIVIDEND
$0.00
EX-DIVIDEND DATE
12-04-2024
NEXT EARNINGS DATE
04-29-2025
BETA 
4.07
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,337
AVERAGE 30 VOLUME 
$589,693
Company detail
CEO: Robert M. Dudley
Region: US
Website: transcodetherapeutics.com
Employees: 9
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

TransCode Therapeutics, Inc. engages in the development and commercialization of drugs and diagnostics. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Recent news